<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0007131" disease_type="Neoplastic Process" abbrv="NSCLC">Non-small cell lung cancer</z:e> constitutes about 85% of <z:hpo ids='HP_0000001'>all</z:hpo> newly diagnosed cases of <z:e sem="disease" ids="C0242379" disease_type="Neoplastic Process" abbrv="">lung cancer</z:e> and continues to be the leading cause of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>-related <z:hpo ids='HP_0011420'>deaths</z:hpo> worldwide </plain></SENT>
<SENT sid="1" pm="."><plain>Standard treatment for this devastating disease, such as systemic chemotherapy, has reached a plateau in effectiveness and comes with considerable toxicities </plain></SENT>
<SENT sid="2" pm="."><plain>For <z:hpo ids='HP_0000001'>all</z:hpo> stages of disease fewer than 20% of patients are alive 5 years after diagnosis; for <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastatic disease</z:e> the median survival is less than one year </plain></SENT>
<SENT sid="3" pm="."><plain>Until now, the success of active-specific immunotherapy for <z:hpo ids='HP_0000001'>all</z:hpo> <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> types has been <z:hpo ids='HP_0003745'>sporadic</z:hpo> and unpredictable </plain></SENT>
<SENT sid="4" pm="."><plain>However, the active-specific stimulation of the host's own immune system still holds great promise for achieving non-toxic and durable antitumor responses </plain></SENT>
<SENT sid="5" pm="."><plain>Recently, sipuleucel-T (Provenge(Â®); Dendreon Corp., Seattle, WA) was the first therapeutic <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> vaccine to receive market approval, in this case for advanced <z:hpo ids='HP_0012125'>prostate cancer</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>Other phase III clinical trials using time-dependent endpoints, e.g. in <z:hpo ids='HP_0002861'>melanoma</z:hpo> and follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, have recently turned out positive </plain></SENT>
<SENT sid="7" pm="."><plain>More sophisticated specific vaccines have now also been developed for <z:e sem="disease" ids="C0242379" disease_type="Neoplastic Process" abbrv="">lung cancer</z:e>, which, for long, was not considered an immune-sensitive <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>This may explain why advances in active-specific immunotherapy for <z:e sem="disease" ids="C0242379" disease_type="Neoplastic Process" abbrv="">lung cancer</z:e> lag behind similar efforts in <z:e sem="disease" ids="C0007134" disease_type="Neoplastic Process" abbrv="">renal cell cancer</z:e>, <z:hpo ids='HP_0002861'>melanoma</z:hpo> or <z:hpo ids='HP_0012125'>prostate cancer</z:hpo> </plain></SENT>
<SENT sid="9" pm="."><plain>However, various vaccines are now being evaluated in controlled phase III clinical trials, raising hopes that active-specific immunotherapy may become an additional effective therapy for patients with <z:e sem="disease" ids="C0242379" disease_type="Neoplastic Process" abbrv="">lung cancer</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>This article reviews the most prominent active-specific immunotherapeutic approaches using protein/<z:chebi fb="7" ids="16670">peptide</z:chebi>, whole <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells, and dendritic cells as vaccines for <z:e sem="disease" ids="C0242379" disease_type="Neoplastic Process" abbrv="">lung cancer</z:e> </plain></SENT>
</text></document>